The Calculation of Target Height Reconsidered

Hermanussen, Michael; Cole, Tim J.

doi:10.1159/000069321

Cited by 89 publications

(81 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another topic is the calculation of the target height (mid-parental height). The classical formula of Tanner (average parental height ± 6.5 cm, according to gender) does not take the correlation between parental heights into account, and two alternative formulas have been proposed as being superior [11, 12]. What is even more relevant for studies on the effect of medication on final height is that in the majority of GH studies, including the study by Rachmiel et al [1], no correction is made for secular trend.…”

Section: Methodological Considerationsmentioning

confidence: 99%

Optimizing Growth Hormone Therapy in Growth Hormone Deficient Children: What to Do in the Absence of Hard Evidence?

Wit

2007

Horm Res Paediatr

View full text Add to dashboard Cite

Section: Methodological Considerationsmentioning

confidence: 99%

Optimizing Growth Hormone Therapy in Growth Hormone Deficient Children: What to Do in the Absence of Hard Evidence?

Wit

2007

Horm Res Paediatr

View full text Add to dashboard Cite

“…Äîâåäåíî, ùî ìàéaeå ó ïîëîâèíè ä³òåé, õâîðèõ íà ²Í, ÿê³ íå îòðèìóâàëè ë³êó-âàííÿ, ÊÇ º íèae÷èì â³ä ö³ëüîâîãî. Çà íàÿâ-íîñò³ çàòðèìêè ê³ñòêîâîãî â³êó õâîð³ íà ²Í ìà-þòü çàäîâ³ëüíèé ÊÇ ³ á³ëüøå øàíñ³â äîñÿãòè ö³ëüîâîãî çðîñòó [10][11][12].…”

Section: ідіопатична низькорослість: клініко-діагностичні критеріїunclassified

Idiopathic short stature: Clinical-diagnostic criteria

Bolshova¹,

Самсон²,

Спринчук³

et al. 2013

CE&ES

View full text Add to dashboard Cite

“…cTH, which is the target height corrected for the effect of assortative mating and parent-offspring correlations, was calculated using the formula: cHT SDSZ0.72!the average of father's and mother's height SDS (21).…”

Section: Outcome Parametersmentioning

confidence: 99%

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Gool

Kamp

Odink

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To assess the long-term effect of prepubertal high-dose GH treatment on growth in children with idiopathic short stature (ISS). Design and methods: Forty children with no signs of puberty, age at start 4-8 years (girls) or 4-10 years (boys), height SDS !K2.0 SDS, and birth length OK2.0 SDS, were randomly allocated to receive GH at a dose of 2 mg/m 2 per day (equivalent to 75 mg/kg per day at start and 64 mg/kg per day at stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of treatment with low or intermediate doses of GH separated by two washout periods of 3 months) or no treatment. In 28 cases, adult height (AH) was assessed at a mean (S.D.) age of 20.4 (2.3) years. Results: GH-treated children (mean treatment period on high-dose GH 2.3 years (range 1.2-5.0 years)) showed an increased mean height SDS at discontinuation of the treatment compared with the controls (K1.3 (0.8) SDS versus K2.6 (0.8) SDS respectively). However, bone maturation was significantly accelerated in the GH-treated group compared with the controls (1.6 (0.4) versus 1.0 (0.2) years per year, respectively), and pubertal onset tended to advance. After an untreated interval of 3-12 years, AH was K2.1 (0.7) and K1.9 (0.6) in the GH-treated and control groups respectively. Age was a positive predictor of adult height gain. Conclusion: High-dose GH treatment restricted to the prepubertal period in young ISS children augments height gain during treatment, but accelerates bone maturation, resulting in a similar adult height compared with the untreated controls.

show abstract

The Calculation of Target Height Reconsidered

Cited by 89 publications

References 14 publications

Optimizing Growth Hormone Therapy in Growth Hormone Deficient Children: What to Do in the Absence of Hard Evidence?

Optimizing Growth Hormone Therapy in Growth Hormone Deficient Children: What to Do in the Absence of Hard Evidence?

Idiopathic short stature: Clinical-diagnostic criteria

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Contact Info

Product

Resources

About